Bristol-Myers Squibb Company – FDA 483, Feb 19, 2021
Celgene Corporation, a Bristol Myers Squibb Company, a CAR-T Cell Manufacturer in Summit, NJ, was cited for three observations during an FDA inspection. The observations primarily concern inadequate aseptic practices leading to potential microbial contamination, failures within the quality control unit regarding material storage and temperature monitoring, and a lack of written procedures for managing escalated deviations and product recalls. These issues indicate significant deficiencies in maintaining product quality and regulatory compliance.
ID · de025911-4ac0-4553-854c-d1edad23420a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.